Abstract

Introduction: Diabetic foot ulcer is one of the most common conditions encountered in surgical OPD. The incidence of a diabetic foot ulcer is around 15% among the diabetic population. Around 80% of non-traumatic amputation is due to chronic diabetic foot ulcer. Recent advances are made in treating wounds in which platelet-rich plasma (PRP) and platelet rich fibrin matrix (PRFM) therapy have proven beneficial. Materials and Methods: A prospective study was conducted from February 2021 to February 2023, for a period of 2 years which included 42 patients. Group A received autologous platelet rich plasma therapy (PRP) and group B received autologous platelet rich fibrin matrix therapy (PRFM) each consisting of 21 patients. Results: PRFM Group showed better reduction in ulcer size compared to respective PRP Group, and demonstrated statistically significant p-values. Around 47% of the subjects had complete closure of the ulcer after 5 sessions of PRP dressing while it was 90% with PRFM dressing. Conclusion: PRFM is better modality to treat diabetic foot ulcer when compared to PRP therapy

• 1.   Ahmad J. The diabetic foot. Diabetes Metab Syndr. 2016;10:48–60.
• 2.   Crawford F, Nicolson DJ, Amanna AE, Martin A, Gupta S, Leese GP et.al. Preventing foot ulceration in diabetes: systematic review and meta-analyses of RCT data. Diabetologia. 2020;63(1):49-64.
• 3.   Government of India, Ministry of Health & Family Welfare: standard treatment guidelines - the diabetic foot - prevention and management in India - full background document (draft) [Jun;2020];http://clinicalestablishments.gov.in/ WriteReadData/5381.pdf January. 2016 & Family Welfare Government of India.
• 4.   Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet. 2003;361(9368):1545-51.
• 5.   Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293(2):217-28.
• 6.   Yazdanpanah L, Shahbazian H, Nazari I, Arti HR, Ahmadi F, Mohammadianinejad SE, et.al. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018:7631659.
• 7.   Assoian RK, Fleurdelys BE, Stevenson HC, Miller PJ, Madtes DK, Raines EW et.al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci U S A. 1987;84(17):6020-24.
• 8.   Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C et.al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998;77(6):956-64.
• 9.   Kaplan DR, Chao FC, Stiles CD, Antoniades HN, Scher CD. Platelet alpha granules contain a growth factor for fibroblasts. Blood. 1979;53(6):1043-52.
• 10.   Liao HT, Marra KG, Rubin JP. Application of platelet-rich plasma and platelet-rich fibrin in fat grafting: basic science and literature review. Tissue Eng Part B Rev. 2014;20(4):267-76.
• 11.   Chignon-Sicard B, Georgiou CA, Fontas E, David S, Dumas P, Ihrai T et.al. Efficacy of leukocyteand platelet-rich fibrin in wound healing: a randomized controlled clinical trial. Plast Reconstr Surg. 2012;130(6):819e-29e.
• 12.   Borie E, Oliví DG, Orsi IA, Garlet K, Weber B, Beltrán V et.al. Platelet-rich fibrin application in dentistry: a literature review. Int J Clin Exp Med. 2015;8(5):7922-29.
• 13.   Suchetha A, Lakshmi P, Bhat D, Mundinamane DB, Soorya KV, Bharwani GA. Platelet concentration in platelet concentrates and periodontal regenerationunscrambling the ambiguity. Contemp Clin Dent. 2015;6(4):510-16.
• 14.   Yazawa M, Ogata H, Nakajima T, Mori T, Watanabe N, Handa M. Basic studies on the clinical applications of platelet-rich plasma. Cell Transplant. 2003;12(5):509-18.
• 15.   Dohan Ehrenfest DM, Bielecki T, Jimbo R, Barbé G, Del Corso M, Inchingolo F et.al. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyteand platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol. 2012;13(7):1145-52.
• 16.   Dorjay K, Sinha S. Platelet-rich Fibrin in Nonhealing Leg Ulcers: A Simple and Effective Therapeutic Option. J Cutan Aesthet Surg. 2021;14(2):160-65.
• 17.   Wang Y, Wang X, Chen R, Gu L, Liu D, Ruan S, Cao H. The Role of Leukocyte-PlateletRich Fibrin in Promoting Wound Healing in Diabetic Foot Ulcers. Int J Low Extrem Wounds. 2021:15347346211052811.
• 18.   Sarvajnamurthy S, Suryanarayan S, Budamakuntala L, Suresh DH. Autologous platelet rich plasma in chronic venous ulcers: study of 17 cases. J Cutan Aesthet Surg. 2013;6(2):97-9.
• 19.   Thorat V, Khan IM, Gaikwad S. Platelet rich fibrin matrix the cost effective way to treat trophic ulcer in diabetes: A pilot study. Medical Science. 2020;24(104):2752-59.

Data Sharing Statement

Funding